Upsher-Smith Updates FDA Regulatory Information for Diltiazem Hydrochloride, a Generic Drug for Hypertension and Angina
Upsher-Smith's Regulatory Update Following Acquisition by Bora Pharmaceuticals
Upsher-Smith Laboratories, acquired by Bora Pharmaceuticals (6472.TW) in April 2024 for $210 million, has updated the FDA regulatory information for its Diltiazem Hydrochloride Extended-Release Capsules (ANDA 205231). This update demonstrates the company's commitment to maintaining the integrity of its generic portfolio in the U.S. and adhering to regulatory standards following the acquisition. Bora Pharmaceuticals aims to leverage Upsher-Smith's manufacturing capabilities with its global contract development and manufacturing organization (CDMO) business to strengthen its presence in the North American market. Transparent management of regulatory data is essential for building trust with distribution channels.
Mechanism of Action and Clinical Value of L-Type Calcium Channel Blockers
Diltiazem Hydrochloride is a non-dihydropyridine calcium channel blocker (CCB) that selectively blocks L-type calcium channels in the cell membranes of cardiac and vascular smooth muscle cells. By inhibiting the influx of calcium ions into cells, it dilates coronary and peripheral blood vessels, reducing blood pressure and alleviating symptoms of chronic stable angina. This approved generic is available in five strengths, ranging from 120mg to 360mg, in extended-release formulations, enhancing patient convenience. Its simultaneous heart rate control effect makes it a widely prescribed standard treatment option for patients with both hypertension and angina.
Market Position and Intense Generic Competition
This drug has demonstrated bioequivalence to Bausch Health's (BHC) original brand drug, Tiazac, and received final approval from the FDA on August 30, 2018. The global diltiazem market is expected to grow from approximately $588.06 million in 2025 to approximately $1.698 billion in 2034, with a compound annual growth rate of 12.53%, driven by the increasing prevalence of cardiovascular diseases and an aging population. The market is characterized by intense price and market share competition among major global generic companies such as Teva, Sandoz, and Viatris. In this competitive landscape, timely updates to regulatory data are crucial for defending market share.
Creating CDMO Synergies Through Supply Chain Stability
The cardiovascular generic market is highly price-sensitive, and even minor supply disruptions can lead to immediate market share losses. Through this FDA regulatory data update, Upsher-Smith has enhanced the transparency of its manufacturing processes and proactively mitigated the risk of drug supply interruptions. This strengthens the credibility of Bora Pharmaceuticals' North American production base and is expected to create positive synergies for its global CDMO business. Close communication with regulatory authorities and effective data management are key indicators of ensuring the continuity of the pharmaceutical supply chain, ultimately contributing to the company's long-term revenue stability.
With Bora Pharmaceuticals' (6472.TW) $210 million acquisition of Upsher-Smith now complete, the update of regulatory data for the marketed Diltiazem Hydrochloride generic (ANDA 205231) serves as an indicator of supply chain stability in the North American market. Given the expected growth of the global diltiazem market to approximately $1.698 billion by 2034, maintaining thorough regulatory history is essential for defending market share against Bausch Health's (BHC) original Tiazac and other competing generic products such as Teva. From an industry perspective, the FDA data update demonstrates validation of manufacturing processes, prevents product recall risks, and solidifies supply chain trust with distributors, acting as a practical safeguard. In the medium to long term, it is expected to enhance the credibility of Upsher-Smith's local production facilities, thereby expanding Bora Pharmaceuticals' opportunities to secure global CDMO contracts. As a result, this regulatory data management will ensure long-term partnerships with major distribution vendors and strengthen the generic business unit's role as a stable cash cow.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA205231